Loading…
Immunological studies confirmed Dectin-1 and CR3 receptor-mediated immune activation by Agarikon polysaccharides in macrophage and dendritic cell cultures. NK cell cytotoxicity enhancement demonstrated in vitro. The December 2020 FDA Phase 1 safety trial of a 50/50 Agarikon-Turkey Tail blend for COVID-19 applications represents the first formal human safety evaluation. Comprehensive human efficacy trials have not been completed.
Representative pattern: (C₆H₁₀O₅)ₙ
This information is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare practitioner before using any herbal product.
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. This content is for educational purposes only and is not a substitute for professional medical advice.